AstraZeneca leans into GLP-1; Cuts looming at Bayer; Eli Lilly’s obesity approval; Endpoints Slack interview with Matt Gline; and morenews2023-11-11T11:00:43+00:00November 11th, 2023|Endpoints News|
AstraZeneca prepares to live with the IRA, shifting focus of arguments to orphan drug changesnews2023-11-10T20:55:18+00:00November 10th, 2023|Endpoints News|
EMA committee recommends approvals for Lilly’s weight loss drug, Mirati’s KRAS inhibitor and morenews2023-11-10T20:30:08+00:00November 10th, 2023|Endpoints News|
Gilead spotlights its oncology work with first focused branding campaignnews2023-11-10T20:04:18+00:00November 10th, 2023|Endpoints News|
House Republicans threaten to subpoena FDA over Covid research documentsnews2023-11-10T18:58:53+00:00November 10th, 2023|Endpoints News|
Madrigal’s got more positive data for resmetirom, plus news from Aligos and NorthSeanews2023-11-10T16:28:33+00:00November 10th, 2023|Endpoints News|
Vor shares new data for stem cell therapy; Melinta partners with Venatorx on antibiotic under FDA reviewnews2023-11-10T16:16:24+00:00November 10th, 2023|Endpoints News|
Thermo Fisher plans to lay off 97 employees, close facility in Alabamanews2023-11-10T16:05:08+00:00November 10th, 2023|Endpoints News|
Madrigal adds to liver disease awareness efforts as it awaits FDA decision on NASH drugnews2023-11-10T14:24:55+00:00November 10th, 2023|Endpoints News|
Neurocrine cuts Takeda-partnered depression drug, switches focus for seizure therapy after PhII failuresnews2023-11-10T12:23:01+00:00November 10th, 2023|Endpoints News|
